Profound Medical Corp.
PROF
$6.19
-$0.11-1.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 122.04% | 202.97% | 161.20% | 661.68% | 629.77% |
| Total Other Revenue | 18.08% | 33.79% | 31.15% | 26.91% | 21.07% |
| Total Revenue | 50.73% | 67.94% | 59.81% | 75.01% | 48.35% |
| Cost of Revenue | 29.15% | 14.03% | 17.77% | 36.44% | 25.40% |
| Gross Profit | 61.90% | 104.66% | 89.60% | 102.37% | 63.88% |
| SG&A Expenses | 38.54% | 42.00% | 55.22% | 38.80% | 24.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.11% | 34.44% | 40.64% | 32.21% | 21.98% |
| Operating Income | -24.78% | -25.93% | -36.08% | -22.44% | -15.36% |
| Income Before Tax | -52.13% | -24.84% | -45.92% | -12.91% | 2.63% |
| Income Tax Expenses | 12,700.00% | -271.43% | 128.95% | 99.26% | 98.44% |
| Earnings from Continuing Operations | -53.05% | -24.77% | -46.88% | -13.45% | 2.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.05% | -24.77% | -46.88% | -13.45% | 2.20% |
| EBIT | -24.78% | -25.93% | -36.08% | -22.44% | -15.36% |
| EBITDA | -26.67% | -27.46% | -37.91% | -23.53% | -15.85% |
| EPS Basic | -25.16% | 0.37% | -18.99% | 5.57% | 15.97% |
| Normalized Basic EPS | -24.48% | 0.33% | -18.16% | 6.08% | 16.39% |
| EPS Diluted | -25.16% | 0.37% | -18.99% | 5.57% | 15.97% |
| Normalized Diluted EPS | -24.48% | 0.33% | -18.16% | 6.08% | 16.39% |
| Average Basic Shares Outstanding | 21.94% | 22.54% | 20.82% | 18.94% | 16.89% |
| Average Diluted Shares Outstanding | 21.94% | 22.54% | 20.82% | 18.94% | 16.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |